Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Nab-paclitaxel Consolidation in Advanced NSCLC
NCT02684461Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Sep 2016
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Overall Survival up to 60 months. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02684461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684461.